Expert Interview
A 2nd look at Arrowhead Pharmaceuticals’ interim Phase 1/2a clinical data for its RNAi-based obesity programs, including ARO-INHBE (alone and in combination with tirzepatide) and ARO-ALK7.
Ticker(s): ARWRInstitution: University of Pittsburgh Medical Center
- Clinical Associate Professor of Medicine & Endocrinologist at UPMC
- Treats 200+ patients with Type 1 Diabetes and 400 patients with obesity
- Clinical and Research Interest in diabetes technology and multidisciplinary modes of care
What stands out most to you in the interim Phase 1/2a data from Arrowhead Pharmaceuticals, particularly regarding visceral fat reduction and body composition changes in obese patients with type 2 diabetes?
Added By: sara_adminHow clinically meaningful do you find the added weight loss and fat reduction seen with ARO-INHBE in combination with tirzepatide compared with tirzepatide alone in this harder-to-treat diabetic population?
Added By: sara_adminGiven the monotherapy data, how do you view the potential role of targeting the Activin E/ALK7 pathway directly, including the early results seen with ARO-ALK7, relative to incretin-based approaches?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
